Stoke Therapeutics Inc — Cash Flow (NASDAQ:STOK) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities 42.22 M66.91 M31.87 M81.07 M86.85 M 99.23 M Cash from investing activities 1.05 M76.43 M45.88 M105.95 M107.47 M 124.93 M Cash from financing activities 108.11 M1.28 M46.41 M53.01 M131.09 M 5.62 M Free cash flow 41.17 M65.71 M27.9 M79.45 M86.65 M 98.75 M

ニュース

These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.

This Rare Disease Biotech Name Teases Around A Buy Point

A Pair Of AI Stocks Lead 5 Top Performers Onto Best Stock Screens

グッゲンハイム社がバイ評価を開始し、ストーク・セラピューティクス株が急騰

Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating

Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity (NASDAQ:STOK)

Stoke Therapeutics, Inc. (STOK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:STOK) 2026-01-13

Gold Miner Franco-Nevada Hits Record High, Leads 12 Hot Growth Stocks Onto Best Stock Lists

月曜日のプレマーケットセッションで下落しているExelixis、Citigroupなどの大手株

キャンター・フィッツジェラルド社、Stoke Therapeutics株に「オーバーウェイト」評価を維持

Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald

ストーク・セラピューティクス株、第3相試験結果発表の遅延で株価下落